RFL News and Press, Rafael Holdings Inc. Class B From 12/13/21

CRANBURY, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, announced a publication on its Phase 2 clinical trial of CPI-613 ...

Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +37%, Biofrontera BFRI +20%, ABVC BioPharma (NASDAQ:ABVC) +12%, Halozyme Therapeutics (NASDAQ:HALO) +11%, Context Therapeutics CNTX +9%. Losers: Angion Biomedica (NASDAQ:ANGN) -22%, Ensysce Biosciences ...

- Ameet Mallik to Transition CEO Role to Chairman, Howard Jonas, and Will Remain a Highly Engaged Member of the Company’s Board of Directors and Chair Newly Established Transition Committee - - Patrick Fabbio, Chief Financial Officer, to Assume the Additional Role of Pres...

RFL has a large bet on one drug for cancer treatment. This important bet just recently failed to succeed as a treatment for one type of cancer, with other studies ongoing. Aside from some real estate side income, RH is a generic biotech coin flip. For further details see: ...

Rafael Pharmaceuticals (NYSE:RFL) announces that the first patient has been enrolled in the APOLLO 613 Phase 1/2 trial of CPI-613 (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma. Two additional sites have also been opened for enrollment in the tria...

CRANBURY, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, announced that the first patient has been enrolled in the APOLLO 613 Ph...

Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +110%, iRhythm Technologies IRTC +44%, Karyopharm Therapeutics KPTI +31%, Glaukos GKOS +25%, Rafael RFL +15%. Losers: Cardiol Therapeutics CRDL -25%, Bone Biologics (OTCPK:BBLG) -15%, ...

Rafael Pharmaceuticals (NYSE:RFL) announces that the European Medicines Agency (EMA) has granted orphan drug designation to CPI-613 (devimistat) for the treatment of Burkitt’s lymphoma. Shares up more than 7% premarket. CPI-613 (devimistat) is a first-in-class ...

CRANBURY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announced that the European Medicines Agency (EMA) has granted or...

Kahn Brothers’ 13F portfolio value increased from $698M to $710M this quarter. Pfizer, VOXX International, and ViewRay were increased substantially during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~44% of the 13F...